Company news

Bright Minds Biosciences Inc. news in 2026

Bright Minds Biosciences Inc.'s news releases, calls and decks from 2026, newest first.

View company

Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies

November 2, 2026

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

September 30, 2026

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

May 26, 2026

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

January 9, 2026

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

January 7, 2026

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

January 6, 2026

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

January 6, 2026

Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

January 5, 2026

Decks in 2026